Limitations of the analysis: lack of blinding; although statistical power was achieved, further validation with larger sample sizes is still required; with the evolving treatment landscape (development of targeted and immunotherapy), the role of DVDMS-PDT in the treatment of advanced esophageal cancer needs to be further clarified.